FindTrial
Sign In

Analysis of toxic effects and efficacy of tyrosine kinase inhibitors as first line treatment in renal cell canrcinoma.

Retrospective analysis of efficacy and toxicity profile of first line Tyrosine kinase inhibitors in the treatment of metastatic Renal cell carcinoma- Experience from a Tertiary Referral centre.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2015/05/005792
Enrollment
50
Registered
2015-05-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Newly diagnosed patients of metastatic Renal Cell Carcinoma

Interventions

Intervention1: NOT APPLICABLE: NOT APPLICABLE Control Intervention1: NOT APPLICABLE: NOT APPLICABLE

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria : 1. Age more than 18 years. 2. Performance status ECOG 0 to 2. 3. Metastatic RCC with measurable disease. 4. All histopathological diagnosis of renal cell carcinoma. 5. Treated with TKIs (Sorafenib, Sunitinib & Pazopanib) in 1st line setting.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1. Non metastatic RCC. 2. Non measurable disease. 3. Patients progressed on first line treatment. 4. Uncontrolled co morbidities.

Design outcomes

Primary

MeasureTime frame
PRIMARY OUTCOME: 1. To determine PFS (Progression free survival) with first line treatment with Tyrosine Kinase inhibitors (Sunitinib, Sorafenib, Pazopanib) in newly diagnosed patients of metastatic RCC 2.To determine toxicity with these drugs in this group of patients Timepoint: 1. At the end of the study 2. at each follow up visit—

Secondary

MeasureTime frame
Secondary objectives: 1. To determine OS (Overall survival) with first line treatment with Tyrosine Kinase inhibitors (Sunitinib, Sorafenib, Pazopanib) in newly diagnosed patients of metastatic RCC Timepoint: At the end of study—

Countries

India

Contacts

Public ContactDr Bhavesh Poladia

Tata Memorial Hospital

bhaveshpoladia@gmail.com09819151554

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026